Meeting
2023 ASCO Annual Meeting
Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.
Authors
Zofia Piotrowska
Massachusetts General Hospital, Harvard Medical School, Boston, MA
Zofia Piotrowska , Lanyi Nora Chen , Elaine Shum , Cathleen Park , Matthew Guo , Ying Liu , Misha Tran , Jennifer Aline Marks , Mandeep Banwait , Stephen V. Liu , Susan Combs Scott , Christine M. Bestvina , Jonathan W. Riess , Kristen A. Marrone , Richard Delmar Hall , Ryan D. Gentzler , Catherine A. Shu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9108)
DOI
10.1200/JCO.2023.41.16_suppl.9108
Abstract #
9108
Poster Bd #
96
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.
First Author: Adam Jacob Schoenfeld
Poster
2023 ASCO Breakthrough
CRISPincette, and detection of low frequency cancer mutations in ctDNA.
First Author: Jin-Soo Kim
Poster
2023 ASCO Annual Meeting
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).
First Author: Hiroki Izumi
Poster
2022 ASCO Annual Meeting
A cell-free RNA-based next-generation sequencing (NGS) assay for the detection of actionable gene fusions in patients with non–small cell lung cancer (NSCLC).
First Author: Yukti Choudhury